Loading clinical trials...
Loading clinical trials...
A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria
Conditions
Interventions
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Locations
44
United States
Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thunderbird Office
Glendale, Arizona, United States
Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thomas Office
Phoenix, Arizona, United States
Balboa Nephrology Medical Group, Inc. (BNMG) - California Institute of Renal Research (CIRR) - Chula Vista
Chula Vista, California, United States
Balboa Nephrology Medical Group, Inc. (BNMG) - El Centro
El Centro, California, United States
Amicis Research Center - Granada Hills
Granada Hills, California, United States
Balboa Nephrology Medical Group, Inc. (Bnmg) - La Mesa
La Mesa, California, United States
Start Date
December 14, 2023
Primary Completion Date
February 27, 2025
Completion Date
April 23, 2025
Last Updated
July 8, 2025
NCT05398783
NCT07547098
NCT07232537
NCT05196035
NCT06721143
NCT06278207
Lead Sponsor
Mineralys Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions